MiMedx Group, Inc. (MDXG) Partners with Vaporox for Advanced Wound Therapy

We recently published 10 Best Biotech Stocks to Buy Under $10. MiMedx Group, Inc. is placed sixth among them.

MiMedx Group, Inc. (NASDAQ:MDXG) is a biotechnology company based in Marietta, Georgia, specializing in regenerative biologics for advanced wound care and surgical recovery. Its portfolio, developed through the patented PURION process, includes EPIFIX, AMNIOFIX, CELERA™, and EMERGE™, which are widely used in chronic wound management and surgical applications.

MiMedx Group, Inc. (NASDAQ:MDXG) reported a record Q2 2025 with 13% year-over-year net sales growth, driven by strong performance in both Wound and Surgical categories. New products CELERA™ and EMERGE™ saw rapid adoption, while established products AMNIOFIX and AMNIOEFFECT delivered double-digit growth. With its consistent execution and innovative pipeline, the company is increasingly being recognized among the best biotech stocks for investors seeking growth in the regenerative medicine space.

The company also entered a strategic partnership with Vaporox, Inc., integrating its placental allografts with Vaporox’s FDA-cleared Vaporous Hyperoxia Therapy (VHT) device. Targeting difficult-to-heal chronic wounds such as diabetic foot and pressure ulcers, the combination therapy has shown healing rates above 80% at 20 weeks, outperforming standard treatments and demonstrating significant innovation in wound care.

On the policy front, the Centers for Medicare and Medicaid Services (CMS) proposed reimbursement reforms for skin substitutes in July 2025. MiMedx Group, Inc. (NASDAQ:MDXG) has welcomed the changes, emphasizing patient care and cost efficiency, while maintaining active engagement with regulators to shape evolving standards.

While we acknowledge the potential of MDXG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.